FDA Approves Takeda’s Eohilia As First Oral Treatment For Inflammed Esophagus
Eohilia: FDA-approved oral therapy for EoE. Takeda's innovative 2mg/10mL stick packs available by February. Histologic remission achieved in studies.
‘FDA Grants Priority Review Of MDMA-Assisted Therapy For PTSD, Psychedelics Drug Development Company Says’ – Marijuana Moment
https://www.marijuanamoment.net/fda-grants-priority-review-of-mdma-assisted-therapy-for-ptsd-psychedelics-drug-development-company-says/ The Food and Drug Administration (FDA) has agreed to review
Why Is Inherited Rare Disease Focused-Larimar Therapeutics Stock Trading Lower Today?
Explore Larimar Therapeutics' 2 study on nomlabofusp for Friedreich's ataxia. Topline data, increased FXN levels, and FDA discussions for accelerated approval.
FDA Advisors Set To Discuss Abbott’s TriClip For Heart Valve Disorder As Questions On Pivotal Trial Loom
FDA to review Abbott's TriClip G4 System for severe tricuspid regurgitation. Circulatory System Devices Panel meeting and insights from the briefing document.
Jaguar Health Announces Submission Of Orphan Drug Designation Application To The FDA For Crofelemer For Cholera-Related Diarrhea
Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio choleraeCrofelemer previously granted Orphan Drug Designation by the FDA and the EMA for both short bowel syndrome and
FDA Approves Takeda’s EOHILIA, The First And Only Oral Treatment In The U.S. For Eosinophilic Esophagitis
— 12 Weeks of Treatment with EOHILIA May Address Significant Unmet Needs of Patients 11 Years of Age and Older— EoE Is a Chronic Disease That Can Significantly Impact Patients, with Esophageal Inflammation and
Catalent’s Bloomington Plant Making Novo Nordisk’s Obesity Drug Faces FDA Scrutiny Regarding Drug Manufacturing Concerns
Novo Nordisk faces manufacturing challenges and drug shortages for diabetes and weight loss drugs, impacting Wegovy and Ozempic.
Zynex Receives FDA Clearance For Its Next Generation M-Wave Neuromuscular Electrical Stimulation Device
Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today
Aprea Therapeutics Announces Submission Of IND Application For APR-1051, A Next Generation WEE1 Kinase Inhibitor
Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has submitted an
ImmunityBio Quality-Of-Life Study In BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function In The 71% Complete Responders Suggesting A Favorable Risk-Benefit Ratio For N-803 Plus BCG
Patient Reported Outcomes (PROs) based on a May 16, 2022 data cutoff in the QUILT 3.032 trial indicate stability of physical function and global health in patients who completed PRO questionnaires and reached month 24